hsa-miR-3180: Hsa-mir-3180 is a microRNA that has been identified as one of the top five upregulated microRNAs [PMC8034913]. It has been found to be a predictor of 90-day mortality in patients [PMC8890551]. The expression of hsa-mir-3180 has been quantified using TaqMan™ MicroRNA Assays [PMC9519568]. In various studies, hsa-mir-3180 has been shown to be upregulated in tumor samples and associated with poor survival outcomes and higher TNM stage in hepatocellular carcinoma (HCC) patients [PMC10083302]. It has also been found to be overexpressed in HCC and associated with the Hepatitis B, Hepatitis C, and hepatocellular carcinoma pathways, indicating its role in liver carcinogenesis [PMC10083302]. Hsa-mir-3180 has shown a stronger association with HCC patient clinicopathological characteristics compared to hsa-miR-378i, making it a potential biomarker for HCC diagnosis [PMC10083302]. The expression of hsa-mir-3180 is significantly higher in tumor samples compared to healthy samples [PMC10083302]. It is also associated with poor survival outcomes and high TNM stage in gastric carcinoma cell lines [PMC10083302]. The potential target genes of hsa-mir-3180 include CD81 and CDKN1A, which are involved in liver diseases pathways [PMC10083302][PMC9374467][PMC7997684][PMC9526595].